Epigenetic Therapies in Endocrine-Related Cancers: Past Insights and Clinical Progress

Dhruvika Varun(University of Nottingham), Jennie N. Jeyapalan(University of Nottingham), Emad A. Rakha(Nottingham University Hospitals NHS Trust), Maria Haque(University of Nottingham), Catrin S. Rutland(University of Nottingham), Rachel Thompson(University of Nottingham), Nigel P. Mongan(University of Nottingham), Anna E. Harris(University of Nottingham), Corinne L. Woodcock(University of Nottingham), Jorja Jackson-Oxley(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)
Cancers
July 22, 2025
10.3390/cancers17152418
Cited by 4

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
|The Lancet Oncology|2015|282